Journal article

Efficacy and Safety of Lisdexamfetamine Dimesylate and Atomoxetine in the Treatment of Attention-Deficit/Hyperactivity Disorder: a Head-to-Head, Randomized, Double-Blind, Phase IIIb Study

Ralf W Dittmann, Esther Cardo, Peter Nagy, Colleen S Anderson, Ralph Bloomfield, Beatriz Caballero, Nicholas Higgins, Paul Hodgkins, Andrew Lyne, Richard Civil, David Coghill

CNS DRUGS | ADIS INT LTD | Published : 2013


Funding Acknowledgements

This study was supported by funding from Shire. The authors thank the patients and their parents, and the investigators who took part in the study.C. S. Anderson, R. Bloomfield, B. Caballero, R. Civil, N. Higgins, P. Hodgkins and A. Lyne are employees of Shire and own stock/stock options. The following authors have received compensation for serving as consultants or speakers, or they or the institutions they work for have received research support or royalties from the companies or organizations indicated: E. Cardo (Eli Lilly, Health Spanish Ministry Research Fund, Ministry of Education Grant Research, Shire, UCB); D. Coghill (Flynn Pharma, Janssen-Cilag, Lilly, Medice, Novartis, Otsuka, Oxford University Press, Pfizer, Schering-Plough, Shire, UCB, Vifor Pharma); R. W. Dittmann (Ferring, Janssen-Cilag, Lilly, Otsuka, Shire, the German Research Foundation [DFG], the German Ministry of Education and Research [BMBF], the Ministry of Health/the German Regulatory Body [BfArM], the European Union [EU FP7 program], the US National Institute of Mental Health NIMH, and he is a former employee and stockholder of E. Lilly and Co.); P. Nagy (Tourette Syndrome Association of USA, Hungarian Ministry of Education, National Development Agency of Hungary, Otsuka, Shire).